Współczesna Onkologia

Omitting the 5-fluorouracil bolus in metastatic colorectal cancer: impact on survival and toxicity in a retrospective multicentre cohort

Ahmed Sohaib 1
,
Eman H. Hebesh 1
,
Naglaa S. Elabd 2
,
Omnia Korani 3
,
Mohamed T. Amin 4
,
Huda I. Abd-Elhafiz 5
,
Amira M. Badawy 2
,
Samar Hosny 1

  1. Clinical Oncology Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt

  2. Tropical Medicine Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt

  3. Medical Oncology Department, National Cancer Institute, Cairo, Egypt

  4. Radiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt

  5. Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Al Minufya, Egypt


Contemp
Oncol (Pozn) 2026; 30 (2)

DOI: https://doi.org/10.5114/wo.2026.162227
Data publikacji online: 2026/06/05
Article file
Omitting the 5-fluorouracil.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Areepium N, Sapapsap B. The impact of omitting 5-FU bolus from mFOLFOX6 chemotherapy regimen on hematological adverse events among patients with metastatic colorectal cancer. World J Oncol 2023; 14: 392-400.
  2. Sung H, Ferlay J, Siegel RL, et al. CA Cancer J Clin 2021; 71: 209-249.
  3. Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis- Ribeiro M, Bento MJ, et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826.
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: colon cancer. Version 1.2025. Available from: https://www.nccn.org/guidelines (accessed: 10.2025).
  5. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87: 393-399.
  6. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
  7. Jakobsen A, Berglund A, Glimelius B, Frödin JE, Hansen F, Kjaer M, et al. Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. Acta Oncol 2002; 41: 525-531.
  8. Garrido Martínez MT, Rodríguez Jorge M, García Giménez I, Guzmán Ramos MI, Grutzmancher Sáiz S, Aviñó Tarazona V. Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer. Farmacia Hospitalaria 2025; 49: T154-T159.
  9. Piedbois P, Rougier P, Buyse M, Pignon J, Ryan L, Hansen R, et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-308.
  10. Peixoto RD, Coutinho AK, Weschenfelder RF, Prolla G, Rocha D, Andrade AC, et al. Fluorouracil bolus use in infusional regimens among oncologists – a survey by Brazilian group of gastrointestinal tumors. JCO Glob Oncol 2021; 7: 1270-1275.
  11. Chiorean EG. Is it time to forget the 5‑fluorouracil bolus? J Natl Compr Canc Netw 2024; 22: 577.
  12. De Jesus VHF, Camandaroba MPG, Donadio MDS, Cabral A, Mu- niz TP, de Moura Leite L, et al. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma. J Gastrointest Oncol 2018; 9: 694-707.
  13. Elabd NS, Alabassy MM, Seddik RM, Amer AA, Abdelaziz RA, Sohaib A. Type 2 diabetes mellitus and non-metastatic colorectal cancer: a retrospective study on survival and toxicity profiles. Asian Pac J Cancer Prev 2024; 25: 87-94.
  14. Peng C, Saffo S, Oberstein PE, Shusterman M, Thomas C, Bec- ker DJ, et al. Omission of 5-fluorouracil bolus from multidrug regimens for advanced gastrointestinal cancers: a multicenter cohort study. J Natl Compr Canc Netw 2024; 22: 521-527.
  15. Peng C, Saffo S, Shusterman M, Becker DJ, Berlin J, Oberstein PE, et al. Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer. J Clin Oncol 2023; 41: 59-59.
  16. Basilio AJ, Shah AB, Sommerer KR, Chehab S, Bottiglieri SM, Imani­rad I. Impact of empirically eliminating 5-fluorouracil (5-FU) bolus and leucovorin (LV) in patients with metastatic colorectal cancer (mCRC) receiving first-line treatment with mFOLFOX6. J Clin Oncol 2020; 38): 4022.
  17. Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest 2016; 34: 94-104.
  18. Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol 2011; 22: 2604-2609.
  19. Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, et al. Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study. Invest New Drugs 2013; 31: 1321-1329.
  20. Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, et al. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs 2012; 30: 2026-2031.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications